📅 PUBMED DAILY TRIAGE — 2026-05-20

Window: 2026-05-19T09:00Z → 2026-05-20T09:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~60 candidates | Tracked records: 21 High priority: 7 | Standard: 14 | Low/archive: ~17 | Unsolicited finds: 0 Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (Liquid Biopsy / ctDNA)

TR-2026-05-20-001 · PMID 42154530 · Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancer · 9/10 🔴 EARLY_CANCER_DETECTION → J Clin Invest | Prospective phase II, n=68, 185 plasma cfDNA samples | rMDS fragmentomic metric achieves AUC 0.89-0.99 for pembrolizumab response prediction in HNSCC, outperforming PD-L1; predicted responders show significantly improved DFS (HR 2.67, p=0.035). Top hit today.

AI/ML in Clinical Diagnostics

TR-2026-05-20-003 · PMID 42156975 · Development and validation of AI-based model for bladder cancer immunophenotyping using whole slide images · 8/10 🟠 NOVEL_TREATMENT → NPJ Precis Oncol | Multicenter, TCGA + 2 hospitals | AUC 0.922-0.956; outperforms junior AND senior pathologists; Inflamed tumors predict ICI response from routine H&E slides.

TR-2026-05-20-007 · PMID 42157015 · A deep learning system for non-invasive breast cancer diagnosis with multimodal data · 8/10 🔴 EARLY_CANCER_DETECTION (medium confidence — abstract truncated) → Nat Biomed Eng | Multicenter | Multimodal (ultrasound + mammography) DL system for non-invasive breast cancer diagnosis. Full abstract recommended for Phase 2 review.

Novel Therapeutics (Immunotherapy / Targeted)

TR-2026-05-20-004 · PMID 42155306 · Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced NSCLC · 8/10 🟠 NOVEL_TREATMENT → Lung Cancer | Phase Ib, n=31, NCT04772235 | RP2D established; ORR 22.2%, intracranial ORR 33.3% in osimertinib-resistant EGFR-NSCLC. Addresses critical unmet need.

Rare Diseases

TR-2026-05-20-002 · PMID 42156861 · Interpretable fine-tuned LLMs facilitate making genetic test decisions for rare diseases · 9/10 🟢 NEAR_TERM_IMPLEMENTABLE → NPJ Digital Medicine | External validation across healthcare systems | RareDAI (Llama 3.1 + Qwen 3 with chain-of-thought) outperforms traditional ML by 10-20% in guiding gene panel vs. WES/WGS selection for rare disease. Joint top hit.

TR-2026-05-20-005 · PMID 42155004 · Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial · 8/10 🟡 UNDERSERVED_POPULATION → Hepatol Commun | Phase 2, n=9, Wilson disease (ultra-rare) | Significant Cu balance reduction (−6.08 mg cumulative over 21 days), rapid onset day 4, well tolerated.

Aging / Longevity

TR-2026-05-20-006 · PMID 42156953 · A unifying model of stem cell dynamics explains age-related methylation patterns across mammals · 8/10 ⚪ PROMISING_PRELIMINARY → Nat Aging | Large human cohort + 11 mammalian species | SCARLET model: stem cell pool/division-rate ratio (N/s) scales with maximum lifespan — reframes epigenetic clock as readout of stem cell dynamics. Mayo Clinic + Edinburgh.

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies

• PMID 42156943 · EMD impact on pediatric AML HCT outcomes · 7/10 · Treatment Innovation — EBMT registry, n=958; EMD increases RI but not OS in pediatric AML
• PMID 42156944 · VWF/FVIII biomarkers for cGvHD diagnosis and monitoring · 7/10 · Diagnostics — Prospective, n=83 cGvHD; AUC ~0.73 for early cGvHD detection
• PMID 42156735 · Targeting ZMIZ1 induces differentiation in AML · 5/10 · Drug Development — CRISPR screen + small molecule development; high novelty; preclinical cap
• PMID 42156596 · Fufang Zaofan Pills + Western medicine in lower-risk MDS · 5/10 · Treatment Innovation — RCT n=60; ORR 47.5% vs 20% (integrated vs. Western only); preliminary

Liquid Biopsy / Early Detection

• PMID 42154443 · PrPC aptamer enables liquid biopsy detection in CRC · 7/10 · Early Detection — 90.6% sensitivity, 89.0% specificity for CRC exosomal PrPC; Adv Sci
• PMID 42155072 · Biomarkers for pediatric solid tumors (liquid biopsy + immunotherapy) · 6/10 · Diagnostics — ASCO Ed Book review; Dana-Farber + St. Jude authors

AI/ML Diagnostics

• PMID 42157065 · Virtual staining of renal biopsy sections for rapid glomerular yield · 6/10 · Diagnostics — Scanner-agnostic, reagent-free; early QC step before staining

Cardiovascular-Metabolic

• PMID 42156758 · Kynurenic acid mediates epicardial fat-induced lymphatic dysfunction in AF; GLP-1 triple agonist rescues · 7/10 · Treatment Innovation — Nat Commun; new AF pathogenic mechanism; GLP-1 angle
• PMID 42156635 · CBC-derived indices in psoriasis/AD/HS and cardiometabolic risk · 5/10 · Diagnostics — Narrative review; NLR, SII, PIV associations

CBC/ML Hematology

• PMID 42155823 · LASSO ML for ischemic stroke etiology (INSIGHT registry, n=388) · 7/10 · Diagnostics — CBC parameters (platelet, RBC) independently predict CE/AFIB stroke; AUC 0.71-0.73
• PMID 42156868 · EASIX + arterial stiffness predict non-dipper hypertension · 6/10 · Diagnostics — CBC-derived EASIX OR 2.55; combined model AUC 0.755

Precision Oncology / Novel Therapeutics

• PMID 42156608 · Early tumor shrinkage predicts OS in mRCC with ICI combinations · 7/10 · Treatment Innovation — Multicenter, n=169; median OS NR vs 30.8 months by shrinkage group
• PMID 42156983 · CysLTR1 inhibition reprograms myelopoiesis, overcomes anti-PD1 resistance · 5/10 · Treatment Innovation — Nat Cancer; asthma drug repurposing; preclinical; high watch priority
• PMID 42156609 · Prior nephrectomy predicts OS in mRCC NIVO+IPI (multicenter, n=135, 54-mo follow-up) · 6/10 · Treatment Innovation

Rare Diseases

• PMID 42154520 · IPFD bleeding phenotypes: ATHNdataset, n=2302 · 7/10 · Diagnostics — 81.6% unclassified; ICH in 8 patients; significant morbidity gap documented
• PMID 42155072 · (also listed under Liquid Biopsy)

💡 UNSOLICITED FINDS

None today — all high-signal articles fell within watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 3 (PMID 42154530 ⭐, 42154443, 42157015)
• Treatment Innovation: 7 (42155306 ⭐, 42156983, 42156758, 42156944, 42156608, 42156609, 42156943)
• Diagnostics: 6 (42156861 ⭐, 42156975 ⭐, 42155823, 42156868, 42157065, 42154520)
• Drug Development: 2 (42155004 ⭐, 42156735)
• Public Health / Aging: 1 (42156953 ⭐)
• Review: 3 (42155072, 42156635, others)

By evidence maturity:

• Exploratory: 11
• Validated: 7
• Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept ≥5 / highest score):

By source type: peer_reviewed 21 | preprint 0

Topics with zero 8+ articles this run:

• Hematologic malignancies (best: 7/10 — EBMT pediatric AML registry)
• CBC-based diagnostics/ML hematology (best: 7/10 — LASSO stroke etiology) ⚠️ 5th+ consecutive run with 0 HIGH
• Cardiovascular-metabolic (best: 7/10 — AF lymphatic/GLP-1 triple agonist)

🔧 RUN NOTES

• Window: No expansion triggered (21 relevant records found, well above 5-record threshold).
• CBC/ML hematology: ⚠️ Fifth or more consecutive run with 0 HIGH articles. Best candidate today was PMID 42155823 (LASSO stroke etiology, 7/10) — not hematology-specific. Reformulation toward hematology-specific CBC-ML (morphology, differential, blood disorder prediction models) is strongly recommended for next cycle.
• AI/ML topic noise: 229 raw results; excluded non-clinical entries (maize blight disease detection PMID 42157044, pangolin behavior PMID 42157025) before scoring. Watchlist match filter applied manually.
• Alert cap hit: 7 HIGH articles identified; 5 alerts sent per run cap. PMID 42157015 (Nat Biomed Eng breast cancer DL) and PMID 42156953 (Nat Aging SCARLET) not alerted but classified HIGH in JSON.
• Medium confidence flag: PMID 42157015 — efetch truncated abstract at author affiliations; scored 8/10 based on journal (Nat Biomed Eng) + title + institutional context. Recommend Phase 2 full-text review.
• humans[MeSH] aging filter: Effective; no non-human noise in aging results today.
• Unsolicited finds: None this run — all high-signal items matched watchlist topics.
• Rolling note (from state): CBC/ML high-signal drought ongoing since at least May 4. GLP-1 alert streak also comparatively quiet today (best CV-metabolic article scored 7 vs. prior runs with 8+ GLP-1 findings).